Akums Drugs and Pharmaceuticals Ltd Q2 FY26 Results
AKUMSQ2 FY26 ResultsAnnounced 13 Nov 2025, 04:52 pm| Metric | Value (₹ Cr) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 1.0K | 0.6% | 1.5% |
| Total Income | 1.0K | 0.1% | 0.3% |
| Expenditure | 984.22 | 3.0% | 2.7% |
| PBT | 65.67 | 31.3% | 28.3% |
| Net Profit | 42.70 | 34.0% | 35.9% |
| OPM | 9.28% | 3.31pp | 6.25pp |
| NPM | 4.07% | 2.09pp | 2.30pp |
| EPS | 2.66 | 35.9% | 39.1% |
Akums Reports Q2 FY26 Results; Strengthens International Presence
13 Nov 2025 · 13 Nov 2025, 05:48 pm
Summary
Akums Drugs & Pharmaceuticals Ltd., India’s Largest Contract Development and Manufacturing Organizations (CDMO), announced its financial results for the second quarter of FY26. The CDMO segment remained the key contributor with revenue of ₹804 crore. The domestic Branded Formulations business recorded revenue of ₹122 crore, with EBITDA margins improving to 21.6%. The Branded Export segment maintained healthy EBITDA margin of 24.5%. The company reported consolidated revenue of ₹71,018 crore for Q2 FY26. The Hon’ble President of Zambia recently did ground breaking of the pharmaceutical plant, set up as a joint venture between Akums and the Govt. of The Republic of Zambia. Akums will also supply Rivaroxaban tablets in Europe in Q3.
Key Highlights
- 1
CDMO segment revenue: ₹804 crore
- 2
Domestic Branded Formulations business revenue: ₹122 crore
- 3
Branded Export segment EBITDA margin: 24.5%
- 4
Consolidated revenue for Q2 FY26: ₹71,018 crore
- 5
EBITDA for Q2 FY26: ₹94 crore
- 6
PAT for Q2 FY26: ₹243 crore
- 7
H1 FY26 revenue: ₹2,042 crore
- 8
H1 FY26 EBITDA: ₹2,223 crore
- 9
H1 FY26 PAT: ₹107 crore
- 10
Zambian facility aimed at supporting access to quality medicines across the SADC Countries
- 11
First commercial supply of formulations in Europe
- 12
Supply of Rivaroxaban tablets in Europe in Q3
Management Comments
Mr. Sanjeev Jain
Managing Director
Our performance this quarter reflects our focus on long-term priorities in a dynamic business environment. The developments in Zambia and Europe mark important milestones in our ongoing journey of becoming a global CDMO.
Mr. Sandeep Jain
Managing Director
CDMO business is navigating through a complex phase, with continued weakening of API prices and sustained flat volumes in the industry. Akums has outpaced industry volume growth. we remain focused on delivering long term shareholder value by further cementing our leadership position in CDMO business, taking measures to grow our domestic and exports branded business and curtailing losses in API and trade generics.
Informational and educational content only. Not investment advice.